These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 27098617)

  • 1. Immunohistochemical Expression of mTOR in Multiple Myeloma: Retrospective Analysis of 31 Cases, a Clinicopathological Study.
    Stockwin W; Johnson P; Vajpayee N
    Ann Clin Lab Sci; 2016; 46(2):125-31. PubMed ID: 27098617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
    Scott EC; Maziarz RT; Spurgeon SE; Medvedova E; Gajewski J; Reasor-Heard S; Park B; Kratz A; Thomas GV; Loriaux M; Cascio M; Podolak J; Gordon M; Botelho J; Stadtmauer E; Amaravadi R; Vogl DT
    Haematologica; 2017 Jul; 102(7):e261-e265. PubMed ID: 28385778
    [No Abstract]   [Full Text] [Related]  

  • 3. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
    Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
    Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
    Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
    J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway.
    Han K; Xu X; Xu Z; Chen G; Zeng Y; Zhang Z; Cao B; Kong Y; Tang X; Mao X
    Sci Rep; 2015 Sep; 5():12809. PubMed ID: 26329846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.
    Li J; Zhu J; Cao B; Mao X
    Curr Pharm Des; 2014; 20(1):125-35. PubMed ID: 24001224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study.
    Vajpayee N; Burack R; Wang D; Hutchison RE; Gajra A
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):159-63. PubMed ID: 25458080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma.
    Liu Z; Liu H; Li Y; Wang Y; Xing R; Mi F; Xiang C; Fu R
    Int J Mol Med; 2020 Apr; 45(4):1112-1120. PubMed ID: 31985020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
    Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
    Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
    Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
    Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
    Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
    Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.
    Chuang WY; Chang YS; Chao YK; Yeh CJ; Ueng SH; Chang CY; Liu YH; Tseng CK; Chang HK; Wan YL; Hsueh C
    Int J Clin Exp Pathol; 2015; 8(10):12757-65. PubMed ID: 26722465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.
    Seegmiller AC; Wang HY; Hladik C; Chen W
    Arch Pathol Lab Med; 2011 Jun; 135(6):770-5. PubMed ID: 21631271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
    Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
    Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma.
    Leal P; García P; Sandoval A; Letelier P; Brebi P; Ili C; Álvarez H; Tapia O; Roa JC
    Arch Pathol Lab Med; 2013 Apr; 137(4):552-7. PubMed ID: 23544944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: a clinicopathological study.
    Vajpayee N; Thakral C; Gopaluni S; Newman N; Gajra A
    Leuk Res; 2012 Nov; 36(11):1403-9. PubMed ID: 22902049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.